Quantcast
Last updated on April 23, 2014 at 12:16 EDT

Latest Chorea Stories

2014-03-24 08:28:14

LA JOLLA, Calif., March 24, 2014 /PRNewswire/ -- Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced that the company will present at BioCentury's Future Leaders in the Biotech Industry conference. The presentation will be delivered by Pratik Shah, Ph.D., President and CEO of Auspex Pharmaceuticals, at 10:30 a.m. EDT on Friday March...

2014-01-08 08:28:14

LA JOLLA, Calif., Jan. 8, 2014 /PRNewswire/ -- Auspex Pharmaceuticals, Inc., a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the completion of two separate financings totaling $35 million and appointment of a new Board member: -- $20 million Series E equity financing led by Deerfield Management Company and supported by existing investors, Thomas, McNerney and...

2013-07-11 12:28:02

LA JOLLA, Calif., July 11, 2013 /PRNewswire/ -- Auspex Pharmaceuticals announced today that the first patient has been enrolled in a multi-center Phase 3 pivotal trial of its lead investigational drug, SD-809 for the treatment of involuntary movements (chorea) associated with Huntington's Disease (HD). Top-line data from the trial, designated the First-HD study, are expected in 2014. (Logo: http://photos.prnewswire.com/prnh/20130627/MM40068LOGO) "SD-809 is a deuterated...

2010-03-05 12:33:00

Results achieved over 80 weeks of treatment consistent with statistically significant reduction in chorea demonstrated in pivotal study Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine® (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant...

2008-10-28 06:00:28

By Rita Rubin Baylor College of Medicine neurologist Joseph Jankovic is a patient man. With the Food and Drug Administration's OK, Jankovic has studied the drug tetrabenazine since 1979. Over the years, he estimates, he has dispensed tetrabenazine -- or TBZ, as he calls it -- to 1,000 people with Huntington's disease, probably more than any doctor in the world. Tetrabenazine helps tame the uncontrollable movements, or "chorea," that characterize Huntington's, an inherited...

2008-09-17 09:00:14

Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced it has acquired Prestwick Pharmaceuticals, Inc., a privately held, U.S.-based pharmaceutical company that holds the Canadian and U.S. licensing rights to Xenazine(R) (tetrabenazine tablets). Xenazine(R) was recently approved by the United States Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's disease. Xenazine(R) was granted Orphan Drug designation by the FDA, which provides the product with...

2008-09-17 09:00:14

OVATION Pharmaceuticals, Inc. announced today that it has acquired from Prestwick Pharmaceuticals the exclusive license in the United States to commercialize Xenazine(R) (tetrabenazine), an orphan drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's Disease (HD). Financial terms of the deal were not disclosed. Subsequently, Biovail Corporation, Canada's largest publicly traded pharmaceutical company, acquired Prestwick....

891e7e55db7a0b85faf798c8b9fbf9411
2008-08-18 12:05:00

The U.S. Food and Drug Administration announced approval of Xenazine (tetrabenazine) for the treatment of chorea in people with Huntington's disease. The FDA said Xenazine is a new drug and the first treatment of any kind approved in the United States for any symptom of Huntington's disease. Currently there are no other drugs that are FDA-approved to treat chorea -- the jerky, involuntary movement that occurs in people with the disease. The federal agency said side effects reported with use...

2008-08-15 18:00:26

NEW YORK, Aug. 15 /PRNewswire/ -- The Hereditary Disease Foundation (HDF) is extremely pleased the U.S. Food and Drug Administration has approved Xenazine, or tetrabenazine, for the treatment of chorea associated with Huntington's disease. "Chorea is a major cause of disability and death in patients with Huntington's disease. Chorea is not just a mere inconvenience; it can prevent Huntington's disease patients from walking, talking, working, watching television and almost every aspect of...

2008-08-15 15:00:14

WASHINGTON, Aug. 15 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved XENAZINE(R) (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). XENAZINE is the first and only FDA-approved treatment for any symptom of HD and is expected to be available later this year. "Until today, physicians and patients had no FDA-approved treatments for...